Independent 2nd opinion of high-cost specialty drugs to ensure evidence-based care and management of the patient’s condition.

The rise in the use and cost of specialty drug therapies to treat rare diseases has become a top concern for pharmacy benefit managers. Independent review by Medical Review Institute of America (MRIoA) ensures patients receive the clinically appropriate specialty drugs.